Fallopian Tube Cancer Treatment in Ahmedabad

This is the question most newly-diagnosed patients ask first. The honest answer: yes, for treatment purposes, they are treated as the same disease.

For most of the last century, doctors thought ovarian cancer started in the ovary. Modern research has shown that a large share of cancers labelled “ovarian” actually start in the end of the fallopian tube and then spread quickly to the ovary. Under the microscope, fallopian tube cancer, ovarian cancer, and primary peritoneal cancer all look like the same disease — and they respond to the same treatments.

What this means for you:

• Your surgery, your chemotherapy, and your follow-up will be the same as for ovarian cancer
• Treatment guidelines (ESGO, NCCN, FIGO) group all three together
• If you have a BRCA mutation, your family’s testing and risk-reducing options are the same as for an ovarian cancer family
• The detailed patient guide for symptoms, recovery, cost, and what to expect is on our Ovarian Cancer page →

This page focuses on what is unique to fallopian tube cancer: the STIC pathway, BRCA-related risk, risk-reducing surgery (RRSO), and tube-only salpingectomy. For everything else, use our Ovarian Cancer guide.

Tap any section to jump:

• 🧬 My report says STIC — what does that mean?
• 📖 What fallopian tube cancer is,
• 🩺 Symptoms
• 🔬 How it is diagnosed
• ❓ Can it be cured?
• 💊 Treatment options
• 🧪 Should I be tested for BRCA?
• 🛡️ Risk-reducing surgery (RRSO) for BRCA carriers
• ⏳ Tube-only salpingectomy — delaying ovary removal
• 👨‍👩‍👧 Should my sister or daughter be tested?
• ✈️ Sending reports before travelling
• 💰 Cost — same as ovarian
• 🏥 Recovery
• 💬 FAQ — 10 questions families ask most

Many women come to this page because their pathology report uses a term called STIC. Here is what that means,.

STIC stands for Serous Tubal Intraepithelial Carcinoma. It is a very early change in the cells at the far end of the fallopian tube. STIC is considered a pre-cancer — it is not invasive cancer yet, but it is the earliest stage on the pathway that can lead to high-grade serous ovarian or fallopian tube cancer.

STIC is usually found in two ways:

1. By accident — during routine surgery for something else (like a hysterectomy for fibroids), when the removed tubes are examined closely under the microscope
2. During risk-reducing surgery — when a BRCA carrier has her tubes and ovaries removed as planned RRSO

If your report says STIC:

• It does not mean you have invasive cancer
• It does mean a close look at the rest of the tubes and ovaries is important
• BRCA testing is recommended, because STIC is strongly associated with BRCA1 and BRCA2 mutations
• Follow-up usually includes regular pelvic examinations and CA-125 tests, depending on what else was found at surgery
• Your treatment plan depends on what else was seen at surgery and whether you carry a BRCA mutation

If STIC was found at surgery and the rest of the specimen was clear, the outlook is excellent. Many women with isolated STIC need no further treatment beyond planned follow-up.

📱 Contact Our Care Team

The fallopian tubes are two thin tubes — one on each side — that connect the ovaries to the womb. Each month, an egg released by the ovary travels down the tube. Cancer can start in the cells lining this tube, most often at the far end (the part closest to the ovary, called the fimbriated end).

Fallopian tube cancer is rare — only about 1–2% of all gynaecological cancers are labelled as primarily fallopian tube in origin. But as we now know, many cancers labelled “ovarian” actually started in the tube.

Two main types:

• High-grade serous carcinoma — the most common type. Treated as part of the ovarian cancer family. Strongly linked to BRCA1 / BRCA2 mutations.
• Other types (endometrioid, clear cell, mucinous) — much rarer.

Fallopian tube cancer does not have specific symptoms of its own. The symptoms are the same as for ovarian cancer, because the two are so closely linked.

Watch for:

• Bloating that does not go away after a few weeks
• Pelvic or belly pain
• Feeling full quickly when eating
• Needing to pass urine more often or more urgently
• Unexplained weight loss or tiredness
• A change in bowel habits

Each of these has many possible causes, and most are not cancer. But if symptoms have lasted more than 3 weeks and are unusual for you, please see a doctor. A pelvic ultrasound and a CA-125 blood test can be done quickly.

For a full symptom explainer, see our Ovarian Cancer page →.

The diagnostic pathway is the same as for ovarian cancer:

• Pelvic ultrasound (transvaginal) — often the first scan
• CA-125 blood test — a cancer marker that is often raised
• CT scan of the chest, belly, and pelvis — to check the extent
• Pelvic MRI — sometimes added to plan surgery
• PET-CT — used in selected cases
• Surgical biopsy — most fallopian tube cancers are confirmed at the time of surgery, not before. A small number are picked up incidentally at surgery for something else.

If a BRCA mutation is suspected (family history of ovarian, breast, or fallopian cancer), genetic testing is offered at the time of diagnosis.

In most cases, yes — especially when it is found early and surgery is followed by chemotherapy. The honest picture,:

Your specific outlook depends on the stage, your general health, whether the tumour can be fully removed at surgery, and whether you carry a BRCA mutation (BRCA-positive cancers often respond better to chemotherapy and to a class of medicines called PARP inhibitors).

you will receive a clear, honest picture for your specific cancer once she has reviewed your reports.

Treatment of fallopian tube cancer is the same as for ovarian cancer.

• Cytoreductive (tumour-clearance) surgery — the cornerstone. The aim is to remove all visible cancer.
• Chemotherapy — usually carboplatin + paclitaxel, given every 3 weeks for 6 cycles. May be given before surgery (neoadjuvant) in selected cases, or after surgery, or both.
• Targeted therapy — bevacizumab (Avastin) is sometimes added.
• PARP inhibitors (olaparib, niraparib, rucaparib) — maintenance medicines for BRCA-positive and HRD-positive cancers, given for up to 2 years after chemotherapy.
• Genetic counselling and BRCA testing — offered to every patient.

For the full patient-language treatment walkthrough — including what to expect day by day, recovery, side effects, and how to talk to your family — see our Ovarian Cancer page →.

📱 Contact Our Care Team

Yes — BRCA testing is now recommended for every woman diagnosed with fallopian tube, ovarian, or primary peritoneal cancer, regardless of family history. National and international guidelines (NCCN, ESGO, ICMR) agree on this.

BRCA testing is also recommended if you have not been diagnosed with cancer, but:

• A close relative (mother, sister, daughter, aunt) has had ovarian, fallopian, or primary peritoneal cancer
• A close relative has had breast cancer before age 50
• A close relative has had male breast cancer or pancreatic cancer
• You have Ashkenazi Jewish ancestry (small but distinct population in India)
• A known BRCA mutation runs in your family

Testing is a simple blood test or a saliva sample, usually arranged with a genetic counsellor. Results take 3–6 weeks.

If you are positive for BRCA1 or BRCA2, the next conversation is about risk-reducing surgery (next section), enhanced breast screening, and cascade testing for your relatives.

📱 Contact Our Care Team

If you carry a BRCA1 or BRCA2 mutation, the most effective way to lower your risk of ovarian and fallopian tube cancer is risk-reducing surgery — removing both fallopian tubes and both ovaries. The medical name is RRSO (risk-reducing salpingo-oophorectomy).

When is it recommended? (per NCCN and ESGO 2023 guidance)

• BRCA1 carriers: between age 35 and 40, or after childbearing is complete
• BRCA2 carriers: between age 40 and 45, or after childbearing is complete

What the surgery involves:

• Keyhole (laparoscopic) or robotic surgery — small cuts, usually 1–2 nights in hospital
• Both fallopian tubes and both ovaries are removed
• The womb is usually not removed unless there is a separate reason to do so
• Recovery is around 2–3 weeks

What changes for you after RRSO:

• Your risk of ovarian and fallopian tube cancer drops by about 80–90%
• Your risk of breast cancer drops by around 50% if surgery is done before menopause
• You will enter surgical menopause if you were not already menopausal — hot flushes, sleep changes, and bone-health changes can occur
• Hormone replacement therapy (HRT) is usually safe and recommended until the natural age of menopause for BRCA1 carriers without breast cancer history — this is discussed in detail before surgery

This is a major decision and should be made calmly, with full information, and on your timeline.

📱 Contact Our Care Team

For some BRCA carriers — particularly younger women not yet ready for surgical menopause — an emerging option is to remove only the fallopian tubes first, and remove the ovaries later. This is called bilateral salpingectomy with delayed oophorectomy.

The reasoning: because many BRCA-related cancers start at the far end of the fallopian tube, removing the tubes first is thought to remove a large share of the cancer risk while keeping the ovaries in place for their hormonal protection. The ovaries are then removed later, closer to the natural age of menopause.

Important context:

• This is an emerging approach — long-term data are still being collected through international trials (notably the WISP and SOROCk studies)
• It is not yet a full replacement for the standard RRSO timing recommended by NCCN and ESGO
• It may allow some women to delay ovary removal until later — particularly relevant for younger BRCA carriers who would otherwise face surgical menopause in their 30s or early 40s
• The decision must be made together with a women’s cancer specialist and a genetic counsellor, based on your specific mutation, your age, your family planning, and your personal preferences

Dr. Nishtha discusses this option with eligible BRCA carriers as part of a wider RRSO consultation.

📱 Contact Our Care Team

If you carry a BRCA mutation, each of your first-degree relatives — sisters, brothers, sons, daughters, parents — has a 50% chance of carrying the same mutation. Testing them is called cascade testing and it is a powerful way to protect your family.

Who to start with:

• Adult sisters and daughters first (highest immediate benefit)
• Adult brothers and sons (BRCA mutations affect men too — breast, pancreatic, and prostate cancer risk)
• Parents (helps trace which side the mutation came from)

Children under 18 are not usually tested for adult-onset cancer genes — testing is offered once they are old enough to make the decision themselves.

A genetic counsellor will explain what to test, what the results mean, and how to talk to relatives — including how to manage the emotional side of starting these conversations.

📱 Contact Our Care Team

Many patients travel to Ahmedabad from across Gujarat, Maharashtra, Rajasthan, and Madhya Pradesh for women’s cancer care.

If you already have scans, biopsy reports, discharge summaries, or treatment records, our care team may request copies of these while helping coordinate your appointment. This helps the care team prepare for your consultation and guide you on the next administrative steps.

Records that are useful to bring (or share when the team requests them):

• Pathology report (including any mention of STIC)
• CT / MRI / PET-CT report and scan images
• BRCA test result (if done) and family history details
• CA-125 and other tumour markers
• A list of current medicines and allergies

How the visit usually works:

1. Contact our care team to discuss what you need
2. Share your available records if the team requests them while coordinating your appointment
3. Attend your in-clinic specialist consultation
4. You leave with a written treatment plan from the specialist

📱 Contact Our Care Team

Because fallopian tube cancer is treated as part of the ovarian cancer family, the cost structure is the same. You will see the same surgery packages (cytoreductive surgery), the same chemotherapy regimens, and the same hospital stay patterns as for ovarian cancer.

For exact published price ranges, see our dedicated cost page:

👉 Ovarian Cancer Treatment Cost in India →

That page covers:

• Cytoreductive surgery package range
• Chemotherapy cost per cycle and full course
• HIPEC if indicated
• PET-CT and pre-treatment scans
• Maintenance PARP inhibitor cost
• PMJAY and insurance coverage

For a personalised quote based on your specific stage, planned surgery, and chemotherapy plan, contact our care team. You will receive a written quote.

📱 Contact Our Care Team

Fallopian tube cancer treatment is covered by most health insurance policies in India, including Mediclaim, ECHS, CGHS, and corporate group policies — on the same basis as ovarian cancer. Whether your specific surgery and chemotherapy are covered, and how much, depends on your policy and your insurer’s approval.

PMJAY (Ayushman Bharat) and MA-Amrutam cover treatment at approved hospitals up to defined caps. PARP inhibitor maintenance therapy may need specific pre-authorisation — coverage varies by policy.

We help with pre-authorisation paperwork, cashless facility at Sterling Hospitals (subject to approval), and reimbursement documentation. Send a copy of your policy on WhatsApp and we will tell you what is likely to be covered.

Recovery from fallopian tube cancer surgery is the same as for ovarian cancer surgery. For the full patient-language recovery walkthrough — hospital stay, when you can walk, eat, drive, return to work, and chemotherapy schedule — see our Ovarian Cancer page →.

Brief summary:

• Keyhole / robotic surgery (early-stage): hospital 2–4 days; back to gentle daily activity in 2–3 weeks
• Open cytoreductive surgery (advanced-stage): hospital 5–10 days; back to gentle daily activity in 4–6 weeks
• Chemotherapy (usually starts 4–6 weeks after surgery): 6 cycles over about 4 months
• PARP inhibitor maintenance (BRCA-positive): up to 2 years

• ESGO-certified women’s cancer specialist
• 12+ years of experience with fallopian tube, ovarian, and peritoneal cancer surgery
• Performs comprehensive cytoreductive surgery — including bowel, peritoneal, and upper-abdominal procedures where needed for full clearance
• Offers RRSO and tube-only salpingectomy for BRCA carriers
• Coordinates with genetic counsellors for BRCA testing and family cascade testing
• Coordinates with medical oncology for chemotherapy and PARP inhibitor maintenance planning
• WhatsApp accessible — direct review of pathology, BRCA results, and family history before your specialist consultation
• Out-of-city families welcomed — pre-travel WhatsApp review saves wasted trips

Read Dr. Nishtha’s Full Profile →   Book Appointment

1. A private conversation about your symptoms, diagnosis, family history, and what brings you in
2. A review of your reports — pathology, scans, BRCA results, and any earlier treatment
3. A brief examination if appropriate, with a female chaperone always present
4. A plain-English explanation of what was seen, what the recommended next step is, and what your options are
5. A written summary and quote by WhatsApp

First appointments take about 30–45 minutes. Family members are welcome.

• Sterling Hospitals, Gurukul Road, Ahmedabad — main centre
• KD Hospital, Vaishnodevi Circle — satellite OPD
• Welcare Hospital, Vadodara — satellite OPD

See locations and timings →

Whether you have a new diagnosis, a recent report, or would like an in-clinic second opinion on a treatment plan — book an appointment with the clinic. The specialist will go through everything with you at your visit.

Dr. Nishtha sees patients at Sterling Hospitals (main centre), KD Hospital, and Welcare Hospital.

📅 Book Appointment   📱 Contact Our Care Team

You can also call the clinic on +91 76988 00333.